SequelSEC

Edwards Lifesciences Corp EW

Orthopedic, Prosthetic & Surgical Appliances & Supplies · CIK 0001099800 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$6.51B
Fiscal year ended 2026-06-30
Operating income
$1.45B
Fiscal year ended 2026-06-30
Free cash flow
$1.43B
Fiscal year ended 2026-06-30

Edwards Lifesciences Corp (EW) reported revenue of $6.51B and net income of $1.00B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Edwards Lifesciences Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Orthopedic, Prosthetic & Surgical Appliances & Supplies.

Income

Edwards Lifesciences Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$6.51B
Cost of revenue$1.44B
Gross profit$5.07B
Operating income$1.45B
Net income$1.00B
Research & development$1.09B
Weighted-average diluted sharesUnavailable
Pretax income$1.42B
Income tax expense$439.00M
Diluted EPSUnavailable
Selling, general & administrative$2.20B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Edwards Lifesciences Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.91B
Total assets$13.87B
Current assets$6.82B
Total liabilities$3.14B
Current liabilities$1.51B
Total equity incl. NCI$10.72B
Temporary (mezzanine) equityUnavailable
Inventory$1.13B
Accounts receivable$770.40M
Goodwill$1.95B
Long-term debt$598.70M
Accounts payable$210.50M

Cash flow

Edwards Lifesciences Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$1.72B
Capital expenditures$286.70M
Investing cash flow-$912.10M
Financing cash flow-$1.20B
Net change in cash-$380.30M
Stock-based compensation$168.00M
Common dividends paidUnavailable
Common share repurchases$1.20B
Depreciation & amortization$165.50M

Derived

Edwards Lifesciences Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$1.43B
Gross margin77.8%
Operating margin22.3%
FCF margin22.0%
SBC / revenue2.6%
Current ratio4.52x
Revenue YoY growth14.6%
Net margin15.4%
R&D / revenue16.7%
CapEx / revenue4.4%
Long-term debt / equity0.06x
Effective tax rate31.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EW in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

ALGN APT AVR BBLG CDRE COCH ENOV ESTA FEED INGN ISRG LAKE

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.